General Information of Drug (ID: DMTEY8W)

Drug Name
E-6276
Synonyms
1-(2-Benzhydrylideneaminooxy-ethyl)-1,2,5,6-tetrahydro-pyridine-3-carboxylic acid; UNII-BGU9MZ2G30; BGU9MZ2G30; CHEMBL473104; 159094-94-7; Tocris-1779; Lopac-N-142; Biomol-NT_000271; AC1L1IC7; Lopac0_000880; SCHEMBL5969062; GTPL4669; BPBio1_000948; CTK0H8642; CHEBI:92744; DTXSID30166582; ZINC1534967; BDBM50426075; BDBM50080344; AKOS030543350; CCG-204962; 3-Pyridinecarboxylic acid, 1-(2-(((diphenylmethylene)amino)oxy)ethyl)-1,2,5,6-tetrahydro-; NCGC00015712-05; NCGC00015712-02; NCGC00025293-03; NCGC00025293-02; NCGC00015712-04; NCGC00025293-01; NCGC00015712-03; NCGC00015712-01; LS-187291
Indication
Disease Entry ICD 11 Status REF
Schizophrenia 6A20 Terminated [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 350.4
Logarithm of the Partition Coefficient (xlogp) 1.5
Rotatable Bond Count (rotbonds) 7
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 5
Chemical Identifiers
Formula
C21H22N2O3
IUPAC Name
1-[2-(benzhydrylideneamino)oxyethyl]-3,6-dihydro-2H-pyridine-5-carboxylic acid
Canonical SMILES
C1CN(CC(=C1)C(=O)O)CCON=C(C2=CC=CC=C2)C3=CC=CC=C3
InChI
InChI=1S/C21H22N2O3/c24-21(25)19-12-7-13-23(16-19)14-15-26-22-20(17-8-3-1-4-9-17)18-10-5-2-6-11-18/h1-6,8-12H,7,13-16H2,(H,24,25)
InChIKey
NGNALWDRPKNJGR-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
4515
ChEBI ID
CHEBI:92744
CAS Number
159094-94-7
TTD ID
D0B7BX

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Opioid receptor sigma 1 (OPRS1) TT5TPI6 SGMR1_HUMAN Binder [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Schizophrenia
ICD Disease Classification 6A20
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Opioid receptor sigma 1 (OPRS1) DTT SIGMAR1 2.77E-06 -0.12 -0.62
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.